-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16

Benzinga·10/30/2025 15:19:15
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences (NYSE:RCUS) with a Neutral and raises the price target from $14 to $16.